Navigation Links
Synvista Therapeutics Appoints William Federici to its Board of Directors
Date:10/10/2008

ople with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure. Diastolic heart failure represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database.

For more information, please visit the Company's Web site at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Ann
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
2. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster
4. Cell Therapeutics Regains Compliance with NASDAQs Minimum Bid Price Requirement
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
6. Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
7. Afid Therapeutics Inc.s New Anticoagulant Heparin Replacement Passes in Vivo Test
8. Industry Experts and Global Regulators to Discuss Oligonucleotide-Based Therapeutics Issues
9. Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
10. TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results
11. Clinical Research Management gets contract for trials of therapeutics against infectious diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... For patients with locally advanced pancreatic cancer, the ... may be a promising treatment option, ultimately allowing ... be an option, according to research presented today ... 56th Annual Meeting. , Surgery is the only ... adenocarcinoma (PDA), the most common type of pancreatic ...
(Date:9/16/2014)... The Pain Center of Arizona (TPC), ... has selected Analance ™, Ducen ’s BI ... TPC seeing hundreds of thousands of patients annually, the ... through “home grown” systems trying to piece together actionable ... “Our current tools were not scalable and, in ...
(Date:9/16/2014)... September 16, 2014 Cloud based ... Streaming (HLS) & UStream API’S to serve m3u8 streams ... feature for broadcasting live video events with hundreds of ... , The App Builder is known for making beautiful ... iOS, BlackBerry and Windows 8 and already over 100,000 ...
(Date:9/16/2014)... reduce the risk of heart disease or stroke, even ... part of the diet. , A study of ... from Monash University,s Department of Epidemiology and Preventive Medicine ... consumption of dairy foods had played in the country,s ... dominantly Chinese food culture, unaccustomed to dairy foods, consuming ...
(Date:9/16/2014)... workers die in motor vehicles than any other workplace ... to address at an international conference being hosted by ... Queensland (CARRS-Q). , The Occupational Safety in Transport Conference ... September 18 and 19 brings together experts from all ... mining to improve workplace health and safety. , CARRS-Q ...
Breaking Medicine News(10 mins):Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:A heart-felt need for dairy food 2Health News:CARRS-Q Host International Transport Safety Conference 2
... ... AZ (Vocus) December 23, 2008 -- Adding to a growing body of ... the December 23rd issue of Circulation further emphasized the need to exercise ... most Americans fall far short of the minimum recommended guidelines of physical ...
... Center for Clinical and Translational Science (CCTS) has ... third annual pilot-project grant program. The grants, which ... early studies in translational science that, if successful, ... CCTS, established through funds from a 2006 Clinical ...
... dangers, researchers say , , TUESDAY, Dec. 23 (HealthDay News) ... in the United States combine over-the-counter medications with prescription ... potentially dangerous interactions, a new survey finds. , A ... more than 175,000 emergency department visits for adverse drug ...
... sports such as swimming had greater bone density in menopause ... exercise during adolescence may help women maintain their bone strength ... Dec. 22 in the British Journal of Sports Medicine ... the teenage exercise habits of 46 postmenopausal women, now aged ...
... perihepatic capsules with concomitant pelvic inflammation. The pain ... main symptom. These cases have to be cautiously ... is pain in the right upper abdomen Fitz-Hugh-Curtis ... that can be diagnosed by non-invasive methoids and ...
... presenting cells (APCs) that both initiate and modulate the ... antigen capture and presentation to T cells, with the ... T cells. Gastric cancer is one of the most ... progress, it is still difficult to treat advanced gastric ...
Cached Medicine News:Health News:Treadmill Desks to the Rescue: Weight Control and Activity Critical in Preventing Heart Failure 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 3Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 4Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4Health News:What is the clinical character of Fitz-Hugh-Curtis syndrome? 2Health News:A new light on tumor immunotherapy for gastric cancer 2
(Date:9/16/2014)... Russia,s ... The Pharma 2020 Strategy provides incentives for local producers ... and foreign markets. These trends, however, were affected by ... following political and economic sanctions imposed on ... Russia responded to the ...
(Date:9/16/2014)... 2014 Research and Markets ... Laparoscopy Devices Industry Report 2014" report to ... Devices Industry Report 2014 is a professional and ... global laparoscopic devices. The report provides ... classifications, applications and industry chain structure. The laparoscopic ...
(Date:9/16/2014)... Sept. 16, 2014 Based on its ... Frost & Sullivan recognises Incisive Surgical with the ... Value Leadership. Incisive Surgical,s uniquely-designed, innovative INSORB® Absorbable ... eliminates the need for patients to undergo the ... removal  that may result in increased pain, wound ...
Breaking Medicine Technology:Global Medicines for Russia 2Global Laparoscopy Devices Industry Report 2014 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5
... Nov. 5, 2010 EnVivo Pharmaceuticals today announced it ... agonist, possesses a novel mechanism not previously seen in ... Acetylcholine (ACh) to enhance cognition. By acting ... makes it possible for smaller amounts of naturally occurring ...
... Nov. 5, 2010 Cadence Pharmaceuticals, Inc. (Nasdaq: ... developing and commercializing proprietary product candidates principally for use ... the three and nine months ended September 30, 2010. ... U.S. Food and Drug Administration (FDA) approved OFIRMEV™ (acetaminophen) ...
Cached Medicine Technology:EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 2Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 3Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 4Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 5Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results 6
...
Liquichek Elevated CRP Control is a liquid assayed serum control with elevated levels of C-Reactive Protein....
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Liquichek Cardiac Markers Plus Control is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: